1. Home
  2. NVO vs MA Comparison

NVO vs MA Comparison

Compare NVO & MA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVO
  • MA
  • Stock Information
  • Founded
  • NVO 1923
  • MA 1966
  • Country
  • NVO Denmark
  • MA United States
  • Employees
  • NVO N/A
  • MA N/A
  • Industry
  • NVO Biotechnology: Biological Products (No Diagnostic Substances)
  • MA Business Services
  • Sector
  • NVO Health Care
  • MA Consumer Discretionary
  • Exchange
  • NVO Nasdaq
  • MA Nasdaq
  • Market Cap
  • NVO 530.0B
  • MA 515.5B
  • IPO Year
  • NVO N/A
  • MA 2006
  • Fundamental
  • Price
  • NVO $88.08
  • MA $557.50
  • Analyst Decision
  • NVO Strong Buy
  • MA Buy
  • Analyst Count
  • NVO 4
  • MA 26
  • Target Price
  • NVO $141.67
  • MA $609.12
  • AVG Volume (30 Days)
  • NVO 9.5M
  • MA 2.6M
  • Earning Date
  • NVO 02-05-2025
  • MA 01-30-2025
  • Dividend Yield
  • NVO 1.48%
  • MA 0.55%
  • EPS Growth
  • NVO 21.54
  • MA 17.41
  • EPS
  • NVO 3.14
  • MA 13.89
  • Revenue
  • NVO $40,314,376,667.00
  • MA $28,167,000,000.00
  • Revenue This Year
  • NVO $21.96
  • MA $15.34
  • Revenue Next Year
  • NVO $17.13
  • MA $12.46
  • P/E Ratio
  • NVO $26.45
  • MA $40.14
  • Revenue Growth
  • NVO 25.03
  • MA 12.23
  • 52 Week Low
  • NVO $77.82
  • MA $428.86
  • 52 Week High
  • NVO $148.15
  • MA $576.94
  • Technical
  • Relative Strength Index (RSI)
  • NVO 56.29
  • MA 54.10
  • Support Level
  • NVO $77.82
  • MA $561.52
  • Resistance Level
  • NVO $88.95
  • MA $570.70
  • Average True Range (ATR)
  • NVO 1.88
  • MA 7.68
  • MACD
  • NVO 0.71
  • MA -1.39
  • Stochastic Oscillator
  • NVO 89.92
  • MA 30.72

About NVO Novo Nordisk A/S

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

About MA Mastercard Incorporated

Mastercard is the second-largest payment processor in the world, having processed close to over $9 trillion in volume during 2023. Mastercard operates in over 200 countries and processes transactions in over 150 currencies.

Share on Social Networks: